SV

Street Verdict

Analyst Scorecard

LALPATHLAB · NSE

Dr. Lal Path Labs Ltd.

₹1,896.9

-1.44% (-₹27.8)

Prev. close

₹1,924.7

Volume

4,77,275

Delivery %

64.2%

As of

18 Sept 2026

Price history

₹1,896.9+₹328.2 (+20.92%) · 3M
10 Jun 2026 → 18 Sept 2026
₹1,954₹1,568.710 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Dr. Lal Path Labs Ltd. in the last 90 days.

Fundamentals

About Dr. Lal Path Labs Ltd.

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. Shankha Banerjee

Headquarters

Gurugram

Employees

5,206

Key stats

Market cap

₹31,674.01 Cr

P/E ratio (TTM)

58.7

Dividend yield

1.04%

EPS (TTM)

₹32.33

Beta (1Y · daily vs NIFTY 50)

0.53

Beta (5Y · monthly vs NIFTY 50)

0.90

Shares float

7.57 Cr

EPS · quarter ended Jun 2026

₹10.13

Upcoming earnings

23 Oct 2026

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹-20%0%20%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

010203040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0246₹-100%0%100%200%05 Mar 2018 Nov 2009 Feb 2120 Jul 2118 Aug 2122 Jun 2205 Aug 2211 Aug 2313 Feb 2410 Jun 2420 Aug 2405 Nov 2405 Feb 2506 Jun 2506 Aug 2507 Nov 2505 Feb 2625 Jun 2630 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,581.30 Cr₹2,087.40 Cr₹2,016.90 Cr₹2,226.60 Cr₹2,461.40 Cr₹2,762.90 Cr
EBITDA₹487.60 Cr₹613.20 Cr₹531.60 Cr₹678.50 Cr₹788.90 Cr₹853.70 Cr
₹291.60 Cr₹344.80 Cr₹238.90 Cr₹357.70 Cr₹487.10 Cr₹504.80 Cr
Diluted EPS₹17.63₹20.79₹14.37₹21.49₹29.2₹30.2

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,661.00 Cr₹2,343.00 Cr₹2,383.00 Cr₹2,454.00 Cr₹2,713.00 Cr₹3,140.00 Cr
—₹532.57 Cr₹419.50 Cr₹246.93 Cr₹157.43 Cr₹198.99 Cr
Stockholders' equity₹1,245.00 Cr₹1,501.00 Cr₹1,666.00 Cr₹1,849.00 Cr₹2,173.00 Cr₹2,509.00 Cr

Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹398.00 Cr₹447.00 Cr₹456.00 Cr₹535.00 Cr₹569.00 Cr₹636.00 Cr
Investing cash flow₹-212.00 Cr₹-449.20 Cr₹-287.30 Cr₹-24.30 Cr₹-303.10 Cr₹-421.90 Cr
₹-139.00 Cr₹136.00 Cr₹-283.00 Cr₹-414.00 Cr₹-334.00 Cr₹-264.00 Cr
Capital expenditure₹-60.00 Cr₹-476.00 Cr₹-45.00 Cr₹-57.00 Cr₹-54.00 Cr₹-173.00 Cr
End cash position₹244.30 Cr₹378.20 Cr₹263.70 Cr₹360.90 Cr₹292.60 Cr₹242.80 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25–Dec 25(2Q)Mar 26Jun 26
Promoter55.23%55.23%55.23%55.05%55.05%55.05%55.03%55.01%54.61%54.60%54.60%54.60%53.92%53.91%53.91%53.79%53.21%53.21%53.21%53.19%
Public43.97%44.03%44.07%44.35%44.38%44.39%44.45%44.55%44.98%45.03%45.08%45.10%45.75%45.81%45.83%45.82%46.42%46.44%46.44%46.43%
Employee trusts0.80%0.74%0.70%0.60%0.58%0.56%0.51%0.44%0.41%0.37%0.32%0.30%0.33%0.28%0.27%0.39%0.37%0.35%0.34%0.38%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Dr. Lal Path Labs Ltd.₹31,709.67 Cr₹1,924.758.512.6420.1%0.08+12.3%-41.0%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

IPO documents

Annual reports

Show all 11

Concall transcripts

Show all 12

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

17 indices

Nifty MidSmall Healthcare· 2.2%Nifty Smallcap 50· 1.8%Nifty Smallcap250 Momentum Quality 100· 1.4%NIFTY Smallcap 100· 1.2%Nifty500 Healthcare· 1.0%Nifty500 Multicap Momentum Quality 50· 0.9%Nifty Total Market Momentum Quality 50· 0.9%Nifty MidSmallcap400 Momentum Quality 100· 0.6%Nifty Smallcap 500· 0.5%Nifty MidSmallcap 400· 0.2%Nifty MidSmallcap400 50:50· 0.2%Nifty 500· 0.1%

Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.

LALPATHLAB

Dr. Lal Path Labs (LALPATHLAB.NS) Slips 0.56% to ₹1,895.7 as Support at ₹1,800.91 Comes Into Focus - Up Down Volume

siam.in · 2 days ago

LALPATHLAB

Dr. Lal Path Labs Ltd (LALPATHLAB.NS) Q2 2026 Earnings

siam.in · 3 days ago